Transaction · 0001159036-26-000108

Torley Helen

Torley Helen, PRES, reported a transaction classified as exercise at HALOZYME THERAPEUTICS, INC. involving 20000.000000 shares for an estimated $368200.00. Reported holdings after the transaction were 787780.000000 shares. The stored filing text includes a detected 10b5-1 reference.

exerciseSEC transaction code MPRES
HALOHALOZYME THERAPEUTICS, INC.
Trade date
Aug 18, 2026
Filing date
Aug 20, 2026
View on SEC Insider profile
Estimated value$368kShares × reported price
Shares traded20.0k$18.41 per share
Holdings after787kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

HALO price since this filing

Daily closing prices, with the filing date and available return windows
HALO · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -26.7%1w ago -3.3%1d ago -2.9%
Returns since7d +0.8%30d +6.0%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
exercise
Code M
Identifier
0001159036-26-000108
Common Stock
Transaction date
Aug 18, 2026
Filed Aug 20, 2026, 12:01 AM · 2d delay
Shares
20,000 sh
$18.41 per share
Estimated value
$368k
Computed from shares × price
Holdings after
787,780 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership 10b5-1 Detected
Filing-only score

0 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

PRESIDENT AND CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales

  2. of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028.

  3. F2

    Represents a weighted average sales price per share. The shares were sold at prices ranging from $98.580 to $99.210. The Reporting Person has provided to the issuer, and will provide to any security

  4. (5 footnotes)

    holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

  5. F3

    Represents a weighted average sales price per share. The shares were sold at prices ranging from $99.980 to $100.780. The Reporting Person has provided to the issuer, and will provide to any security

  6. F4

    Represents a weighted average sales price per share. The shares were sold at prices ranging from $101.140 to $102.120. The Reporting Person has provided to the issuer, and will provide to any security…

  7. F5

    Represents a weighted average sales price per share. The shares were sold at prices ranging from $102.140 to $103.050. The Reporting Person has provided to the issuer, and will provide to any security…

  8. F6

    Represents a weighted average sales price per share. The shares were sold at prices ranging from $103.160 to $104.010. The Reporting Person has provided to the issuer, and will provide to any security…

  9. F7

    Represents a weighted average sales price per share. The shares were sold at prices ranging from $102.550 to $103.540. The Reporting Person has provided to the issuer, and will provide to any security…

  10. F8

    Represents a weighted average sales price per share. The shares were sold at prices ranging from $103.570 to $104.550. The Reporting Person has provided to the issuer, and will provide to any security…

  11. F9

    Represents a weighted average sales price per share. The shares were sold at prices ranging from $104.585 to $105.080 The Reporting Person has provided to the issuer, and will provide to any security…

  12. F10

    Represents a weighted average sales price per share. The shares were sold at prices ranging from $105.69 to $106.680 The Reporting Person has provided to the issuer, and will provide to any security h…

  13. F11

    Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.69 to $107.680 The Reporting Person has provided to the issuer, and will provide to any security h…

  14. F12

    Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.69 to $107.900 The Reporting Person has provided to the issuer, and will provide to any security h…

  15. F13

    Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant

  16. was February 14, 2018.

Original filing · 0001159036-26-000108
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

HALO